GEN-MKT-18-7897-A
Apr 28, 2026 | Biopharma, BioPhase 8800 system, Blogs | 0 comments
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Native fluorescence detection (NFD) strengthens CE‑SDS performance by improving both detection sensitivity and interpretability.
High sensitivity without labeling
NFD leverages intrinsic tryptophan fluorescence to detect proteins label‑free, avoiding the variability and workflow burden of dye‑labeling steps.
Technical note data show:
For scientists managing stability programs or performing forced degradation studies, this sensitivity can reveal early‑stage degradation signatures that UV cannot reliably resolve.
Clearer, more stable baselines for better integration
Typical UV electropherograms show baseline drifting due to buffer absorbance and gel heterogeneity.
The NFD baseline, however, is consistently flat, improving:
These benefits reduce manual reprocessing and strengthen data defensibility across development stages.
Multi-capillary throughput for faster studies
The BioPhase 8800 system processes 8 samples in parallel, expanding CE‑SDS throughput without requiring additional instruments or longer sequences.
High‑throughput CE‑SDS paired with NFD’s sensitivity provides a strong foundation for data‑driven therapeutic development.
A balanced upgrade path from UV and LIF
NFD complements existing detection modes:
This offers scientists flexibility while building long‑term method robustness.
Explore the CE‑SDS NFD data
For deeper review, check out the resources in our NFD solutions hub >
Glycosylation is one of the more structurally diverse and biologically impactful PTMs in protein therapeutics. Both N‑linked and O‑linked glycans influence protein folding, stability, and biological activity. Given these effects on biotherapeutics, glycosylation is a closely monitored critical quality attribute (CQA). Comprehensive and site‑specific characterization of glycosylation is essential for informed decision‑making throughout drug discovery and development.
Warranty expiration is more than an administrative milestone—it is a transition point that can significantly impact instrument uptime, laboratory productivity, operating budgets, and scientific outcomes.
For more than 20 years, the CDCO has supported academic, commercial, and not‑for‑profit drug discovery programs with deep expertise in pharmaceutical lead optimization. Within the bioanalytical group, their role is to enable rapid and reliable decision‑making through quantitative analysis of candidate drugs in biological matrices.
Posted by
You must be logged in to post a comment.
Share this post with your network